Hybrid dopamine uptake blocker–serotonin releaser ligands: A new twist on transporter-focused therapeutics
As part of our program to study neurotransmitter releasers, we report herein a class of hybrid dopamine reuptake inhibitors that display serotonin releasing activity. Hybrid compounds are interesting since they increase the design potential of transporter related compounds and hence represent a novel and unexplored strategy for therapeutic drug discovery. A series of N-alkylpropiophenones was synthesized and assessed for uptake inhibition and release activity using rat brain synaptosomes. Substitution on the aromatic ring yielded compounds that maintained hybrid activity, with the two disubstituted analogues (PAL-787 and PAL-820) having the most potent hybrid activity.
Blough, B., Landavazo, A., Partilla, J. S., Baumann, M. H., Decker, A., Page, K., & Rothman, R. B. (2014). Hybrid dopamine uptake blocker–serotonin releaser ligands: A new twist on transporter-focused therapeutics. ACS Medicinal Chemistry Letters, 5(6), 623-627. DOI: 10.1021/ml500113s